MRK Phase 3 readout: a positive outcome, +12.6%

On August 12, 2026, Enlicitide — MERCK (Hyperlipidemia) reached its Phase 3 readout. The result was a positive outcome, and the stock moved +12.6% in the window around the event. It had already run +9.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.